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Abstract
Directed differentiation of human embryonic stem cells (hESCs) into any desired cell type has been hailed as a therapeutic
promise to cure many human diseases. However, substantial roadblocks still exist for in vitro differentiation of hESCs into
distinct cell types, including T lymphocytes. Here we examined the hematopoietic differentiation potential of six different
hESC lines. We compare their ability to develop into CD34
+ or CD34
+CD45
+ hematopoietic precursor populations under
several differentiation conditions. Comparison of lymphoid potential of hESC derived- and fetal tissue derived-
hematopoietic precursors was also made. We found diverse hematopoietic potential between hESC lines depending on
the culture or passage conditions. In contrast to fetal-derived hematopoietic precursors, none of the CD34
+ precursors
differentiated from hESCs were able to develop further into T cells. These data underscore the difficulties in the current
strategy of hESC forward differentiation and highlight distinct differences between CD34
+ hematopoietic precursors
generated in vitro versus in vivo.
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Introduction
Directed differentiation of human embryonic stem cells (hESCs)
into a variety of cell types has vast promise in the context of
personalized human therapeutics and also towards understanding
developmental paradigms. Specifically, hESC-derived hematopoi-
etic subsets could theoretically be used for a variety of therapeutic
purposes such as replenishment of lymphocyte deficiency due to
chemotherapy, suppression of autoimmunity by regulatory T cells,
or T cell mediated anti-tumor therapy. However, we first need to
establish a robust and repeatable protocol for in vitro differentiation.
Differences in lineage potential among independently derived
hESC lines has been noted for a number of downstream target cell
types and at different stages of development. In addition to gene
expression heterogeneity among the hESC lines themselves,
lineage skewing among hESC lines has been identified as early
as commitment to the three germ layers [1–6]. In other reports,
lineage bias between hESC lines is detected at the latest stages of
development—definitive differentiation of forebrain versus hind-
brain neurons, for example [7]. For the hematopoietic lineage, the
potential of hESCs to develop into blood lineage cells has
primarily been addressed with a restricted number of stem cell
lines and differentiation methods. Several groups have reported
success in generating erythrocytes, various myeloid lineage cells, B
cells, and NK cells from hESCs, albeit differentiation of B cells was
based primarily on expression of lineage markers rather than
functional assays [8–17]. However, generation of T lymphocytes
from the same hESC lines has been difficult to achieve, despite the
fact that mouse ESCs can be easily induced to differentiate toward
the T cell lineage by co-culturing with Notch-1 ligand expressing
stromal cells [18]. One group has verified T lineage potential from
the H1 hESC line through in vivo passage of hESC-derived
hematopoietic progenitor cells in a humanized mouse model
[19,20]. Recently, another group reported generation of T cells
from what they refer to as ‘‘hematopoietic zones’’ in vitro [21]. This
is currently the sole successful report of in vitro T cell dif-
ferentiation. However, under similar conditions, another group
reported a strong lineage bias against the development of T
lineage cells from hESCs, and rather an NK lineage pre-
disposition [15]. These discrepancies in T lineage differentiation
potential between labs using similar protocols, and the low
efficiency of T cell development in successful labs highlights a need
for improved understanding of hESC culture conditions and
differentiation protocols before becoming clinically useful.
The basis for these differences in lineage potential among hESC
lines are not completely understood but could stem from a number
of variables including, but not limited to, genetic background, the
quality and stage of the embryo at derivation, and the hESC
isolation method. In addition, the sensitivity of hESC lines to
experimental variability make it extremely difficult to compare the
differentiation potential of hESC lines indirectly via published
results.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19854Here, we set out to establish the hematopoietic and lymphoid
potential of a sampling of hESC lines from various sources under
different culture conditions and differentiation protocols in a
side-by-side comparison at different stages of differentiation. We
found significant differences in hematopoietic potential among
independent hESC lines, differences in blood lineage develop-
ment under different passage conditions regardless of karyotypic
abnormalities, and disparities under unique directed differenti-
ation protocols. These lineage biases were identified early in
hematopoietic development and also at subsequent stages of
lymphoid development. In contrast, ex vivo hematopoietic
progenitors developed consistently and efficiently into lymphoid
cells, specifically the T cell lineage, under the same in vitro
differentiation conditions.
Results
We sought to compare the hematopoietic potential of several
hESC lines from different sources. In this analysis we included one
human ES cell line reportedly skewed toward mesoderm (HuES8),
one toward endoderm (HuES14), one not described (HuES15), the
two lines most prevalently used by others for hESC-hematopoietic
differentiation, H1 and H9, and another independently-derived
hESC cell line, HSF-6 [4,22,23].
First, we analyzed the proportion of each hESC line that gave
rise to putative hemangioblasts (CD34
+CD45
2) and hematopoi-
etic progenitor cells (CD34
+CD45
+) under various passage and
differentiation parameters (Fig. 1). We compared the affect of
enzymatic (trypsin treatment) versus manual passage on hemato-
Figure 1. Comparative analysis of hemangioblast development from independently-derived hESC lines. Several hESC lines were
differentiated as embryoid bodies (EB) for nine days after several trypsin passages (A, top panel) or after several manual passages (A, middle panel) in
EB media without lineage-skewing cytokines. CD34
+ and CD34
+CD45
+ development was determined by flow cytometric analysis of several cell
surface markers indicative of differentiation state. The proportion of hESC-derived CD34
+CD45
2 cells is presented on differentiating hESCs in black.
The proportion of CD34
+CD45
+ progenitors is indicated in white. HuES8, HuES14, and HuES15 cell lines were highly susceptible to gross karyotypic
abnormalities during trypsin passage (as indicated). H1, H9, and HSF6 manually passaged cells had previously been passaged with trypsin (.5
manual passages before differentiation). (A, bottom panel) Independently-derived hESC were differentiated on an OP9 monolayer for nine days, and
CD34 and CD45 cell surface expression analyzed by flow cytometry. Two representative experiments of each condition are presented. (B) Abnormal
karyotypes observed in trypsin passaged cells. (C) Representative time course of CD34 expression on manually passaged, independently-derived
hESCs differentiated as EBs or on an OP9 monolayer. CD34 expression was analyzed on days 3, 6, 9, 12, 15, 18.
doi:10.1371/journal.pone.0019854.g001
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hematopoietic lineage, we allowed hESCs to differentiate into
embryoid bodies (EB) or co-cultured hESCs on an OP9 mouse
bone marrow stromal cell monolayer in the absence of lineage
skewing cytokines. Consistently, and regardless of cell line, manual
passage gave rise to a higher proportion of hESCs differentiating
to CD34
+ cells in EB culture (Fig. 1A). Under the same
differentiation conditions, enzymatically passaged hESCs also
failed to up-regulate CD45, a marker indicative of hematopoietic
commitment. In contrast, under the same differentiation condi-
tions, CD45 was detectable on all the hESC lines maintained
through manual passage (Fig. 1A). It has been shown that
enzymatic passage of hESCs can lead to an increased frequency of
karyotype abnormalities [6,24]. Therefore, we also performed
karyotype analysis periodically to determine gross karyotypic
changes under different culture conditions. Trypsin-passaged
HuES8, HuES14, and HuES15 hESC cultures consistently
displayed gross karyotype abnormalities (Fig. 1B). However, no
significant karyotype abnormalities were observed in H1 or H9
trypsin-passaged hESC cultures, nor were any chromosomal
abnormalities noted in any of the manually passaged cultures.
All hESC lines used throughout the manuscript maintained
normal karyotypes with the exception of the top panel of
Figure 1A, as noted.
We next analyzed the propensity of manually passaged hESC
lines to generate CD34
+ and CD34
+CD45
+ using a complemen-
tary differentiation system. Undifferentiated hESCs were harvest-
ed and plated on a monolayer of OP9 mouse bone marrow
stromal cells capable of promoting hematopoietic development.
Again, CD34 and CD45 expression were monitored by flow
cytometry. Overall, all hESC lines consistently gave rise to CD34-
expressing cells. However, several differences in the differentiation
potential were noted using the two different protocols. Cell-surface
CD45 was not detected at any time point on hESCs differentiated
in the OP9 co-culture system (Fig. 1A, bottom panel and data not
shown). In addition, although the H1 line consistently had a higher
proportion of CD34
+ cells in both differentiation conditions, other
hESC lines, specifically H9 and HSF6 generated proportionally
more CD34
+ cells in the OP9 co-culture system as compared with
the EB condition. We also observed that the kinetics of cell-surface
CD34 expression differed significantly between hESC lines and
the differentiation protocols (Fig. 1C).
The CD34
+ population contains developmental intermediates
capable of giving rise to multiple lineages. To compare the
potential of CD34
+ cells derived from independent hESC lines,
CD34
+CD45
2 cells from EB cultures were enriched by fluores-
cence activated cell sorting (FACS) and placed into culture with
differentiation media containing lineage-promoting cytokines and
growth factors that provide hematopoietic- or endothelial-skewing
conditions. As expected, under hematopoietic skewing conditions,
CD34
+ cells differentiated into CD45
+VE-cadherin
2 cells
(Fig. 2A), whereas under endothelial skewing conditions, CD34
+
cells up-regulated cell-surface expression of VE-cadherin (Fig. 2B)
[25]. Of the lines generating CD45
+ cells from CD34
+CD45
2
populations (HuES8, HuES14, H1, and H9), the proportion of
CD45
+ cells is comparable (Fig. 2A.) Whether generation of
CD45
+ cells in these conditions is due to loss of non-hematopoietic
committed cells remains to be seen. We also noticed that the
number of CD45
+ cells relative to the starting population varied
among hESC lines and between experiments (Fig. 2C). HuES8, in
particular, showed extensive variability in the generation of
CD45
+ cells between experiments (Fig. 2C). This is in contrast
to the ability of CD34
+ cells from different hESCs to give rise to
endothelial cells, which was more consistent from line to line
(Fig. 2D). Interestingly, H1-derived CD34
+ cells generated
relatively more CD45
+ cells while HSF-6-derived CD34
+ cells
consistently gave rise to relatively more VE-cadherin
+ cells as
compared to other hESC lines (Figs. 2C and 2D).
It has been shown that hESC-derived hematopoietic progenitor
cells differ phenotypically from their in vivo fetal liver or cord blood
counterparts that can easily differentiate into all hematopoietic
lineages, being more similar to primitive blood cell progenitors
[15,26–28]. This difference might be one reason for their inability
to efficiently generate all the blood lineages in vitro. To examine the
possible differences among hematopoietic progenitors, we assessed
the cell-surface expression of a cohort of markers indicative of
hematopoietic differentiation state and maturity. Based on CD34,
CD31, and CD45 expression, hESC-derived cells were more
similar to CD34
+ human fetal liver cells, whereas the majority of
cord blood CD34
+ cells expressed CD45
+ cells (Fig. 3A). Since the
fetal liver and cord blood CD34
+ cells have similar lymphoid
lineage differentiation potential, and the fetal liver CD34+ cells
resemble hESC-derived CD34+ cells, these markers alone cannot
distinguish the in vitro differentiation capacity of CD34
+ cells.
Co-culture of hematopoietic progenitors on the mouse bone
marrow stromal cell line, OP9, is known to support lymphocyte
differentiation from a number of human hematopoietic progenitor
populations [29]. Therefore, we followed the differentiation steps
of hESC-derived CD34
+ cells on an OP9 monolayer by analyzing
the expression of a lymphocyte commitment marker, CD7, by flow
cytometry. As shown in Figure 3B, lines HuES8, HuES14,
HuES15, and H1 gave rise to a small population of CD7
+ cells. In
contrast, H9 or HSF6-derived CD34+ cells did not produce
appreciable CD7
+ cells in OP9 co-culture, and overall, lymphoid
progenitor yield was low among lines (Fig. 3B). In addition, we
analyzed the ability of hESC-derived CD34
+ cells to differentiate
into T cells. To test T lineage differentiation, we co-cultured
hESC-derived CD34
+ cells on OP9 stromal cells that express
human delta-like 1 Notch ligand (OP9-DL1). This system has been
shown to support T lineage differentiation from a variety of mouse
and human progenitor cell sources [18,29,30]. Both human fetal
liver and cord blood CD34
+ cells generate a significant
populations of cells co-expressing CD7 and CD1a marking T
lineage commitment within 14 days of co-culture initiation
(Figs. 3C and 3D). In contrast, no CD7
+CD1a
+ T cell progenitors
were seen in cultures with hESC-derived CD34
+ cells (Figs.
3C and 3D), despite the ability of the same co-culture





hi fetal liver progenitors to CD4
+CD8
+-expressing T
lineage cells (Fig. 3E).
Severalgroupshave attempted similar differentiation ofT lineage
cells from hESC-derived progenitor cells with limited success in vitro.
The only exception was a recent report that purportedly found a
CD34
+CD43
+ population in a structurally distinct ‘‘hematopoietic
zone’’, which can be differentiated into CD4
+CD8
+ T cells by co-
culturing with OP9-DL1 cells [21]. Despite extensive search under
microscopes, however, we could not detect any ‘‘hematopoietic
zones’’ as described in our hESC/OP9-DL1 co-cultures. We also
analyzed expression of CD43 in CD34
+ cells differentiating in the
presence of OP9-DL1 cells. In contrast to cord blood CD34
+ cells
that didgenerate T lineagecellsand express CD43,noexpressionof
CD43 was detected by flow cytometry on differentiating hESC-
derived CD34
+ cells (Fig. 3F).
Discussion
Successful development of directed differentiation protocols for
all hematopoietic lineages from hESC lines would allow not only
Comparative Studies of Human ES Cell Lines
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purposes, but would also permit research into early human blood
cell development that is otherwise inaccessible to observe and
manipulate. Despite the intense interest and investment in
developing blood cell therapies from hESCs, we still lack adequate
understanding of how culture conditions and differentiation
protocols may affect lineage development. Here we present a com-
parison of the developmental potential of six independent hESC
lines maintained and differentiated under multiple parameters.
Unlike previous studies that compare multiple cell culture
conditions for one hESC line, or one differentiation protocol for
multiple hESC lines, our approach was to directly compare
multiple hESC lines under several culture and differentiation
conditions [4,31–34]. This provides a comprehensive side-by-side
analysis of important variables on in vitro blood cell development.
Though we do observe similar lineage potential differences in
some previously compared hESC lines (HuES8, HuES14, and
HuES15), we note additional differences among these lines based
on passage conditions and differentiation method. First, there were
significant developmental differences among the same hESC lines
when passaged under different conditions. Enzymatic passage of
hESCs has been shown to favor karyotype instability [6,24], and as
expected, three of the hESC lines displayed gross karyotype
abnormalities following trypsin passage. Interestingly, H1 and H9
did not exhibit any karyotypic abnormalities under enzymatic
passages. However, the differentiation potential of the enzymat-
ically passaged H1 and H9 cultures as compared to manually
passed H1 and H9 hESCs was dramatically impaired. These data
highlight the need for manual passage of all hESC cell work.
We noted that differentiation into hematopoietic lineages varies
between hESC lines and culture conditions. This is in contrast to
endothelial lineage development, which was more similar between
lines and experiments. This might be attributed to the endothelial
lineage being a ‘‘default’’ pathway during lineage commitment.
Using CD45 as a marker of early hematopoietic commitment, we
found EB-based culture conditions superior to OP9 co-culture
Figure 2. Skewed hematopoietic vs. endothelial potential from EB-derived CD34
+CD45
2 cells. (A) The indicated hESC lines were first
differentiated as EBs in EB media without lineage skewing cytokines. CD34
+CD45
2 cells were enriched by fluorescence activated cell sorting (FACS)
on day 10 of EB culture and differentiated on fibronectin-coated plates in the presence of IL-3, IL-6, SCF, G-CSF, Flt3L, and BMP4 for an additional 7
days. Representative flow cytometry plots of CD45 (hematopoietic marker) and VE-cadherin (endothelial marker) are presented. (B) Comparative
analysis of endothelial potential from independently-derived hESC lines. Endothelial differentiation of hESC lines was determined by a two-step
culture. hESCs were initially differentiated for 9 days as EBs as in (A), and CD34
+ cells enriched by FACS. CD34
+ cells were plated on fibronectin-coated
plates in the presence of an endothelial growth factor cocktail containing bovine pituitary extract, heparin, and hVEGF, and analyzed after 7
additional days in culture. Representative flow cytometry plots of CD45 and VE-cadherin are presented. (C) Graphs depict the relative number of
hematopoietic (CD45
+) or (D) endothelial lineage (VE-cadherin




population. Three independent experiments are shown in (C) and (D). The right panels denote the average of the three independent data sets with
error bars and standard deviation between hESC lines. * denotes p,0.05.
doi:10.1371/journal.pone.0019854.g002
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14, 15 and H1) consistently produced more CD34
+CD45
+ cells.
The hESC line HuES8, for example, could produce up to 40%
CD34
+ cells within 10 days. Under hematopoietic skewing
conditions, CD34
+CD45
2 cells from EB cultures could differen-
tiate into CD45
+ cells. Again, in contrast to the ability of CD34
+
cells from all hESC lines tested to develop into endothelial cells,
only three hESC lines (HuES 8, 14 and H1) consistently
differentiated into the CD45
+ early hematopoietic progenitors. A
similar finding was observed when EB-derived CD34
+ cells were
co-cultured with OP9 cells, and the lymphoid marker, CD7, was
used to measure differentiation into the lymphoid lineages.
We were particularly interested in improving the efficiency of
generating T cells from hESCs by co-culturing CD34
+ cells with
Notch-ligand expressing OP9-DL1 cells. However, despite evidence
from one group that reported development of T lineage cells from
hematopoietic zones in this OP9 co-culture system, we and others
have not been successful in doing so [15,21]. The reasons behind
this are not clear. The comparatively high expression of Id factors in
hESCs and hESC-derived hematopoietic cells as compared to cord
Figure 3. hESC-derived hematopoietic progenitor cells are phenotypically and developmentally distinct from in vivo hematopoietic
precursors. (A) Significant phenotypic differences among hESC-derived, cord blood, and fetal liver hematopoietic progenitor cells. Representative
plots of cell surface expression of CD34, CD31, and CD45 on differentiated hESCs (EB culture for 9 days), and CD34
+ cell enriched cord blood and fetal
liver. (B) Relative number of lymphocyte committed cells (as evidenced by expression CD7) as compared to input population (CD34
+ population
enriched by FACS from day 9 EBs.) Three independent experiments are shown (Exp 1–3). The bottom panel denotes the average of the three
independent data sets (Exp 1–3), after normalization to the fold change of the H1 sample in each experiment. Standard deviations between hESC
cells with p,0.05 (*) are also indicated. (C) Analysis of CD7 and CD1a expression from FACS enriched EB-derived, fetal liver, or cord blood CD34
+ cells
differentiated on OP9-hDL1 co-cultures for 14 days. (D) The proportion of T lineage-committed cells was determined by flow cytometric analysis of
CD7 (lymphocyte) and CD1a (T cell) expression. Duplicate experiments are shown as representative of differentiation of CD34
+ cells into CD7
+ cells in
OP9-hDL1 co-culture conditions (Enriched CD34
+ cells from HuES15, H9, and HSF6 hESC lines failed to expand/survive in co-culture with OP9-hDL1
and are thus not presented). (E) Representative flow plots of cell-surface CD4 and CD8 expression from fetal liver CD34
+ subsets differentiated on OP9
(left) or OP9-hDL1 (center and right) cells for 28 days. Fetal liver cells expressing CD34 were sorted to .95% purity. Additionally, fetal liver subsets




hi populations due to a gradient of CD45 expression. Cells were co-cultured on either OP9 or OP9-
DL1 as indicated. (F) Flow cytometric analysis of cell-surface CD43 staining on HuES8, HuES14, and H1-derived hematopoietic progenitors (EB culture,
day 9) and human cord blood progenitors. Flow plots were gated on CD34
+ cells.
doi:10.1371/journal.pone.0019854.g003
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gonize T lineage development and may be one of the hurdles to in
vitro T cell generation from hESC lines [15]. An additional test of T
lineage potential may be passage of hESC-derived hematopoietic
progenitors through a humanized mouse model. H1 hESC cells
were shown to be capable of differentiating into T cells in vivo
[19,20]. However, we showed that this line under multiple con-
ditions, nevertheless, was unable to differentiate into T cells in vitro.
The difficulty of differentiating hESCs into T cells is in contrast
to the ease in which mouse ESCs develop into CD4
+CD8
+ T cells
in the presence of OP9-DL1 cells. It has been suggested recently
that the majority of hESCs in existence share more similarities to
mouse epiblast cells than mouse ESCs derived from the blastocyst
inner cell mass. Mouse epiblast stem cells are not truly pluripotent
and are characterized by flattened morphology and the inability to
grow from a single cell. Like hESCs, they also differentiate into
teratomas. Thus, it is possible that generating new hESC lines that
are more similar to mouse ESCs might be more conducive for T
cell differentiation. To that end, recent studies isolating hESCs
under controlled oxygen conditions or pushing existing ‘‘epiblast-
like’’ hESCs back to a more pluripotent state by manipulation of
the KLF transcriptional circuitry may provide more consistent
stability of hematopoietic and T cell differentiation [35,36].
Rigorous comparison of independent lines derived under these
conditions will be needed to determine if the more ‘‘primitive’’
hESC lines may present better starting material for robust and
repeatable hESC differentiation in vitro.
Materials and Methods
Ethics statement
This research was reviewed and approved by the UC Berkeley
Stem Cell Research Oversight Committee.
hESC Cell Culture
All hESCs have been described previously [22,23] (see also,
http://stemcells.nih.gov/research/registry/ucsf.asp). hESCs were
maintained on irradiated mouse embryonic feeder cells derived
from C57BL/6 mice (E12.5–E13.5) in knockout-DMEM media as
described [4] (Invitrogen). hESCs were passaged by either
enzymatic passage using 0.05% trypsin or manual passage using
StemPro EZPassage (Invitrogen) and split at a ratio between 1:3 to
1:6[4].hESCsampleswere splitatvarioustimepointsforkaryotype
analysis at the Children’s Hospital Oakland Research Institute.
Differentiation protocols
Embryonic bodies (EBs) from hESCs were formed essentially as
described [4]. hESC colonies were dissociated by adding 1 mg/
mL collagenase IV for 10 minutes at 37uC. Plates were
subsequently washed with PBS and EB media was added (no
cytokines or growth factors). Dissociated colonies were removed
from plates using a cell scraper and transferred into six-well low-
attachment plates (Corning). Half media changes were done every
other day for the duration of EB culture. EBs were dissociated for
flow cytometric analysis or CD34
+ cell enrichment by FACS by
the addition of 1 mg/mL collagenase B (Roche) for 2 hours at
37uC, following by vigorous pipetting.
For hematopoietic and endothelial two-step cultures, 24 or 48
well plates were coated with fibronectin, and sorted, day 9 EB-
derived CD34
+ cells were plated in differentiation media
containing IL-3, IL-6, SCF, G-CSF, Flt3L (PeproTech), and
BMP4 (R&D) (hematopoietic differentiation conditions) or in
Medium-199 with 20% fetal bovine serum (FBS), bovine pituitary
extract (Invitrogen), heparin (Leo Pharma Inc), and hVEGF
(R&D) (endothelial differentiation conditions) for 7 days with
media changes on days 2, 4, and 6 as described [25,37].
For co-culture experiments, hESC cells or FACS enriched EB-
derived CD34
+ cells were plated on OP9 or OP9-DL1 (gift from
JC Zu ´n ˜iga-Pflu ¨cker, University of Toronto) cells in MEM alpha
media with 20% defined FBS as described [16,18,21]. Cultures
were maintained with half media changes every other day up to 18
days. Differentiated cells were liberated by either vigorous
pipetting (FACS enriched CD34
+ cells) or by collagenase IV
treatment at 37uC for 30 minutes followed by a 15 minute
incubation at 37uC with 0.05% trypsin (hESC cultures).
Flow cytometry and cell sorting
CD34
+ cells were initially enriched from human fetal liver (ABR
Inc., Alameda, CA, USA) or human cord blood (NDRI,
Philadelphia, PA, USA) using the EasySep Human CD34 Positive
Selection Kit (Stem Cell Technologies, Vancouver, Canada) for
cell surface marker analysis by flow cytometry. Single cell
suspensions of CD34-enriched fetal liver and cord blood, or
dissociated EB were incubated with fluorochrome conjugated anti-
human CD34 and anti-human CD45 antibodies as indicated, and
washed. Cell suspensions were sorted using a Cytopeia INFLUX
Sorter (BD). For flow cytometry, single cell suspensions were
stained with fluorochrome conjugated anti-human CD34, CD45,
VE-cadherin, CD31, CD7, CD1a, CD4, CD8 and CD43 (R&D
and eBioscience). Sample acquisitions were performed on the
Beckman Coulter Cytomics FC 500 or EPICS XL flow cytometer
(Miami, FL, USA), and data were analyzed with FlowJo software
(Tree Star, Ashland, OR, USA).
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